FOXA1 and Familial prostate cancer: Although the bladder cancer panel achieved high sequencing depth throughout the FOXA1 3′-UTR (Supplementary Fig. 11), only one mutation (a base substitution) was identified among the 53/71 patients with sufficient ctDNA or cancer tissue cellularity (p = 0.04 for comparison with 33/290 in prostate cancer, Fisher’s exact test).